Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866244 | 0.96 | HDAC1 (0.71) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL27768646 | 0.89 | ALDH1A1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL2870864 | 0.88 | HDAC1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL6706804 | 0.85 | ALDH1A1 (0.70) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL3436257 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL893099 | 0.85 | ALDH1A1 (1.00) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL7744184 | 0.84 | HDAC1 (0.69) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL1683862 | 0.84 | ALDH1A1 (0.68) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL2560216 | 0.84 | HDAC1 (0.69) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL27700829 | 0.84 | ALDH1A1 (0.54) | ALDH1A1HDAC1HDAC8HDAC6PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| WO-2005019168-A2 | FLUORINATED LYSINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043292-A1 | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025110621-A1 | NOVEL OXAZOLE-BASED COMPOUND AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING INFLAMMATORY DISEASES COMPRISING SAME | 고려대학교 세종산학협력단 | 2025-05-30 | — | — | WO | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119192103-A | Five-membered heterocyclic amide compound, preparation method and application thereof, and bactericide | 贵州大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016355-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC) ACETYLCHOLINE RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| US-4150143-A | N-Substituted-acylamino-oxazoles as antiasthma agents | LILLY INDUSTRIES LIMITED (GB) | 1979-04-17 | — | — | US | disclosed |
| US-4122183-A | ANTIASTHMATIC | LILLY INDUSTRIES LIMITED (GB) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043292-A1 | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors | DPP4, DPP7, ALPI | ALDH1A1 313/4885HDAC1 234/4885HDAC8 985/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885HDAC1 398/4885HDAC8 381/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | ALDH1A1 130/4885HDAC1 844/4885HDAC8 3467/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | ALDH1A1 1721/4885HDAC1 2333/4885HDAC8 2791/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | ALDH1A1 267/4885HDAC1 1007/4885HDAC8 2046/4885 |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | ALDH1A1 563/4885HDAC1 1337/4885HDAC8 3410/4885 |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | ALDH1A1 130/4885HDAC1 844/4885HDAC8 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.